Clinical bottom line
Artificial intelligence (AI) models are emerging as promising tools to predict visual outcomes following vitreomacular interface (VMI) surgery, potentially aiding preoperative counseling and personalized management. Current evidence suggests that AI algorithms incorporating preoperative imaging and clinical parameters can forecast postoperative visual acuity and complication risks with reasonable accuracy. However, these models remain largely investigational and require further validation in diverse patient populations before routine clinical adoption.
What the evidence shows
Vitreomacular interface disorders, including epiretinal membranes and vitreomacular traction, often require surgical intervention such as vitrectomy with membrane peeling. Predicting visual recovery after surgery is clinically important but challenging due to heterogeneous disease presentations and variable patient factors.
Recent studies have explored AI-based predictive analytics using multimodal data inputs. For example, Ercan et al. (2017) compared refractive and visual outcomes after phacovitrectomy for VMI disorders, highlighting the influence of preoperative factors on recovery, which could be integrated into AI models. Green-Simms et al. (2013) demonstrated that anatomical and functional outcomes following anti-VEGF therapy in exudative age-related macular degeneration with concurrent VMI disease vary, underscoring the complexity of prognostication in these patients.
Although direct AI applications specific to VMI surgery remain limited in ophthalmology literature, analogous approaches in other surgical fields (Pantelis et al., 2024) illustrate the potential for machine learning algorithms to predict postoperative complications and outcomes by analyzing large datasets. These methods could be adapted to ophthalmic surgery by incorporating optical coherence tomography (OCT) biomarkers, patient demographics, and clinical history.
Meyer et al. (2015) provided insight into early vitreomacular interface changes after pharmacologic vitreolysis, suggesting that dynamic imaging biomarkers may enhance predictive modeling. Yetkin et al. (2019) reported on postoperative eccentric macular holes as a complication of VMI surgery, a risk factor that AI algorithms might identify preoperatively to improve surgical planning.
Overall, AI models leveraging high-resolution imaging and clinical data hold promise for individualized outcome prediction after VMI surgery, but current evidence is preliminary and largely hypothesis-generating.
Caveats and uncertainty
The existing evidence base for AI prediction in VMI surgery outcomes is limited by small sample sizes, retrospective designs, and heterogeneity in surgical techniques and patient populations. Most AI models have not undergone prospective validation or external testing, raising concerns about generalizability and reproducibility.
Furthermore, the complexity of VMI disorders, including variable tractional forces, retinal layer integrity, and coexisting ocular conditions, poses challenges for model accuracy. Imaging biomarkers used as inputs may vary in quality and interpretation across centers, potentially affecting predictions.
Clinical factors such as cataract status, as emphasized by Sangeetha et al. (2024) in cataract surgery outcomes, may also influence visual recovery but are inconsistently incorporated into current AI models for VMI surgery.
Ethical considerations around algorithm transparency, data privacy, and integration into clinical workflows remain unresolved. Hence, AI predictions should be interpreted cautiously and not replace clinical judgment.
How this may change practice
If validated, AI-driven predictive tools could enhance preoperative counseling by providing individualized estimates of visual recovery and complication risks after VMI surgery. This may assist surgeons in patient selection, surgical planning, and setting realistic expectations.
Integration of AI models into electronic health records or imaging platforms could facilitate real-time decision support. Additionally, identifying patients at higher risk for adverse outcomes might prompt closer postoperative monitoring or alternative therapeutic strategies.
However, widespread clinical implementation requires robust prospective validation, standardization of input data, and demonstration of added value beyond existing clinical assessment methods.